Bill Doyle of Novocure, a company that developed non-invasive technology to control cell division in glioblastoma tumors, spoke at TEDMED 2012 about the role low intensity alternating electric fields can have on cancer therapy:
Flashbacks: NovoTTF-100A for Treatment of Brain Tumors Wins FDA Clearance; NovoTTF System for Slowing Progression of GBM May Soon Be Available in U.S.; NovoTTF as Effective as Chemotherapy for Recurrent Glioblastoma; NovoTTF-100A Validated in More GBM Patients in Phase III Trial; NovoTTF-100A for Glioblastoma Multiforme